YIH
CNTX icon

Y-Intercept (HK)’s Context Therapeutics CNTX Stock Holding History

Y-Intercept (HK)’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,635
Closed -$89.4K – 1253
2024
Q3 		$89.4K Buy
+45,635
New +$101K 0.01% 1212

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Y-Intercept (HK)'s CNTX Position: Q4 2024 in Review

Y-Intercept (HK) sold out of Context Therapeutics (CNTX) in Q4 2024, closing a stake of 45,635 shares — an estimated $89.4K sold.

Y-Intercept (HK) first reported a position in CNTX in Q3 2024 and held it in 1 quarter. The position peaked at $89.4K in Q3 2024. 52 funds tracked by Wall St. Rank hold CNTX as of Q4 2024.

  • Y-Intercept (HK) reported no remaining Context Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 45,635 Context Therapeutics shares in Q4 2024, an estimated $89.4K.
  • Y-Intercept (HK) first reported a position in Context Therapeutics in Q3 2024 and held it in 1 quarter.
  • Y-Intercept (HK)'s Context Therapeutics position peaked at $89.4K in Q3 2024.
  • 52 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2024.

Based on Y-Intercept (HK)'s 13F filing for Q4 2024, filed 4 Feb 2025.